![](https://cdn1.poz.com/150732_CHFa-24-030.jpg_8595dab3-38b7-4432-8cc1-7a392a16071c_x2.jpg)
“Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer
First-line treatment with Lorbrena (lorlatinib) delayed disease progression at five years in more than half of people with ALK-positive metastatic non-small-cell lung cancer (NSCLC)—the longest progression-free survival ever reported for this type of …